Thrombolysis for acute ischaemic stroke

JM Wardlaw, V Murray, E Berge… - Cochrane database of …, 2014 - cochranelibrary.com
Background Most strokes are due to blockage of an artery in the brain by a blood clot.
Prompt treatment with thrombolytic drugs can restore blood flow before major brain damage …

[HTML][HTML] Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis

JM Wardlaw, V Murray, E Berge, G Del Zoppo… - The Lancet, 2012 - thelancet.com
Background Recombinant tissue plasminogen activator (rt-PA, alteplase) improved
functional outcome in patients treated soon after acute ischaemic stroke in randomised trials …

How to do a systematic review

A Pollock, E Berge - International Journal of Stroke, 2018 - journals.sagepub.com
High quality up-to-date systematic reviews are essential in order to help healthcare
practitioners and researchers keep up-to-date with a large and rapidly growing body of …

European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke

E Berge, W Whiteley, H Audebert… - European stroke …, 2021 - journals.sagepub.com
Intravenous thrombolysis is the only approved systemic reperfusion treatment for patients
with acute ischaemic stroke. These European Stroke Organisation (ESO) guidelines provide …

[HTML][HTML] Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an …

K Rahimi, Z Bidel, M Nazarzadeh, E Copland, D Canoy… - The Lancet, 2021 - thelancet.com
Background The effects of pharmacological blood pressure lowering at normal or high-
normal blood pressure ranges in people with or without pre-existing cardiovascular disease …

The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial

EC Sandset, PMW Bath, G Boysen, D Jatuzis, J Kőrv… - The Lancet, 2011 - thelancet.com
Background Raised blood pressure is common in acute stroke, and is associated with an
increased risk of poor outcomes. We aimed to examine whether careful blood-pressure …

Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial

R Saxena, S Lewis, E Berge, PAG Sandercock… - Stroke, 2001 - Am Heart Assoc
Background and Purpose—We sought to investigate the apparently high risk of early death
after an ischemic stroke among patients with atrial fibrillation (AF), identify the main factors …

Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation

AJ Camm, G Accetta, G Ambrosio, D Atar, JP Bassand… - Heart, 2017 - heart.bmj.com
Objective We studied evolving antithrombotic therapy patterns in patients with newly
diagnosed non-valvular atrial fibrillation (AF) and≥ 1 additional stroke risk factor between …

Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies

KB Slot, E Berge, P Dorman, S Lewis, M Dennis… - Bmj, 2008 - bmj.com
Objective To estimate the impact on long term survival of functional status at six months after
ischaemic stroke. Design Prospective cohort study. Settings Three cohorts: Oxfordshire …

Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation

KMHB Slot, E Berge - Cochrane Database of Systematic …, 2018 - cochranelibrary.com
Background Factor Xa inhibitors and vitamin K antagonists (VKAs) are now recommended in
treatment guidelines for preventing stroke and systemic embolic events in people with atrial …